Sparian Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sparian Biosciences is a privately held, clinical-stage biotech leveraging a CNS-focused drug discovery approach to develop treatments for pain and substance use disorders. Its lead asset, SBS1000, has completed Phase 1 trials, and the company has secured substantial non-dilutive funding, including over $60 million in NIH/NIDA grants. With a pipeline featuring first-in-class mechanisms for opiate and stimulant use disorders, Sparian is positioned as an innovative player in the addiction therapeutics space, though it faces the typical risks of early-stage clinical development.

Central Nervous System (CNS)PainSubstance Use DisordersOpioid Use DisorderStimulant Use Disorder

Technology Platform

Focused on rational drug design of novel small molecules with targeted, often dual-receptor pharmacology (e.g., mu/delta opioid receptors, sigma receptor/dopamine transporter) for central nervous system disorders.

Opportunities

The company is targeting massive, underserved markets driven by public health crises: Opioid Use Disorder (4M+ patients), non-opioid pain, and Stimulant Use Disorder (no approved drugs).

Substantial non-dilutive grant funding validates the science and funds early development.

The NIH HEAL Initiative creates a supportive regulatory and commercial environment for innovative addiction treatments.

Risk Factors

High clinical development risk as all programs are in early stages (preclinical/Phase 1) with novel mechanisms.

Future financing risk looms, as grant funding is insufficient for late-stage trials, requiring a transition to private capital.

Competition exists in OUD from entrenched therapies, and the regulatory path for first-in-class StUD treatments is unproven.

Competitive Landscape

In OUD, Sparian's SBS-226 would compete against standard-of-care drugs like buprenorphine (partial MOR agonist), methadone, and naltrexone, aiming to differentiate on safety (no precipitated withdrawal). In non-opioid pain, the landscape is crowded but still lacks dominant safe-and-effective alternatives to opioids. In StUD, SBS-518 faces no direct pharmacotherapy competitors, positioning it as a potential pioneer if successful.

More companies in United States →